LIVN vs SYRE
LivaNova vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
70
Buy
| Metric | LIVN | SYRE |
|---|
| AI Score |
70
|
70
|
| Price |
$82.25
|
$103.56
|
| P/E Ratio |
23.83×
|
-53.14×
|
| ROE |
-20.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.2%
|
0.0%
|
| Debt / Equity |
0.27×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
60.6
|
54.6
|
| Beta |
0.872
|
3.026
|
| Expected Upside |
+0.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for LIVN versus SYRE.
The committee scores are tied.
LIVN and SYRE both score 70/100.
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical